{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:31:23Z","timestamp":1790872283694,"version":"4.1.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,7,1]]},"DOI":"10.1097\/qai.0b013e3181d0db97","type":"journal-article","created":{"date-parts":[[2010,4,17]],"date-time":"2010-04-17T04:00:33Z","timestamp":1271476833000},"page":"258-268","source":"Crossref","is-referenced-by-count":46,"title":["Laboratory Monitoring to Guide Switching Antiretroviral Therapy in Resource-Limited Settings: Clinical Benefits and Cost-Effectiveness"],"prefix":"10.1097","volume":"54","author":[{"given":"April D","family":"Kimmel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton C","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Anglaret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue J","family":"Goldie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Losina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazdan","family":"Yazdanpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eug\u00e8ne","family":"Messou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara L","family":"Cotich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle P","family":"Walensky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth A","family":"Freedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R5-5-20210131","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S0140-6736(08)60624-8","article-title":"Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model.","volume":"371","author":"Phillips","year":"2008","journal-title":"Lancet"},{"key":"R18-5-20210131","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1056\/NEJMsa060247","article-title":"Cost-effectiveness of HIV treatment in resource-poor settings-the case of Cote dIvoire.","volume":"355","author":"Goldie","year":"2006","journal-title":"N Engl J Med"},{"key":"R19-5-20210131","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1097\/01.aids.0000180101.80888.c6","article-title":"Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV\/AIDS in Cote dIvoire: a trial-based analysis.","volume":"19","author":"Yazdanpanah","year":"2005","journal-title":"AIDS"},{"key":"R20-5-20210131","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/QAD.0b013e328011ec53","article-title":"HIV drug resistance surveillance for prioritizing treatment in resource-limited settings.","volume":"21","author":"Walensky","year":"2007","journal-title":"AIDS"},{"key":"R21-5-20210131","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0140-6736(98)07399-1","article-title":"Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote dIvoire: a randomised trial. Cotrimo-CI Study Group.","volume":"353","author":"Anglaret","year":"1999","journal-title":"Lancet"},{"key":"R22-5-20210131","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2471\/BLT.06.032292","article-title":"Progression to WHO criteria for antiretroviral therapy in a 7-year cohort of adult HIV-1 seroconverters in Abidjan, Cote dIvoire.","volume":"85","author":"Minga","year":"2007","journal-title":"Bull World Health Organ"},{"key":"R23-5-20210131","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1089\/aid.2006.0308","article-title":"Morbidity before and after HAART initiation in sub-Saharan African HIV-infected adults: a recurrent event analysis.","volume":"23","author":"Seyler","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R26-5-20210131","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jama.1996.03540140060028","article-title":"The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine.","volume":"276","author":"Russell","year":"1996","journal-title":"JAMA"},{"key":"R27-5-20210131","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jama.1996.03540160061034","article-title":"Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine.","volume":"276","author":"Siegel","year":"1996","journal-title":"JAMA"},{"key":"R28-5-20210131","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","article-title":"Recommendations of the panel on cost-effectiveness in health and medicine.","volume":"276","author":"Weinstein","year":"1996","journal-title":"JAMA"},{"issue":"Suppl 4","key":"R29-5-20210131","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1097\/01.aids.0000279714.60935.a2","article-title":"Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.","volume":"21","author":"Freedberg","year":"2007","journal-title":"AIDS"},{"key":"R30-5-20210131","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1086\/587184","article-title":"Scaling up antiretroviral therapy in South Africa: the impact of speed on survival.","volume":"197","author":"Walensky","year":"2008","journal-title":"J Infect Dis"},{"key":"R31-5-20210131","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/QAI.0b013e3181594c38","article-title":"The cost-effectiveness of antiretroviral therapy for treating HIV disease in the Caribbean.","volume":"46","author":"Wolf","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R32-5-20210131","doi-asserted-by":"crossref","first-page":"946","DOI":"10.7326\/0003-4819-126-12-199706150-00003","article-title":"Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.","volume":"126","author":"Mellors","year":"1997","journal-title":"Ann Intern Med"},{"key":"R35-5-20210131","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1086\/315334","article-title":"Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection.","volume":"181","author":"Deeks","year":"2000","journal-title":"J Infect Dis"},{"key":"R36-5-20210131","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/aje\/kwg206","article-title":"Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models.","volume":"158","author":"Cole","year":"2003","journal-title":"Am J Epidemiol"},{"key":"R37-5-20210131","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/135965350701200416","article-title":"The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Cote dIvoire.","volume":"12","author":"Losina","year":"2007","journal-title":"Antivir Ther"},{"key":"R38-5-20210131","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/108729104323076007","article-title":"Preventing and managing antiretroviral drug resistance.","volume":"18","author":"Kuritzkes","year":"2004","journal-title":"AIDS Patient Care STDS"},{"key":"R39-5-20210131","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/01.qai.0000245882.28391.0c","article-title":"Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure.","volume":"43","author":"Goetz","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R40-5-20210131","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1097\/QAD.0b013e32830e4cf3","article-title":"Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study.","volume":"22","author":"Lee","year":"2008","journal-title":"AIDS"},{"key":"R41-5-20210131","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1097\/QAD.0b013e32830f97e2","article-title":"Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification.","volume":"22","author":"Petersen","year":"2008","journal-title":"AIDS"},{"key":"R42-5-20210131","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/QAD.0b013e3282f768f8","article-title":"Rapid scaling-up of antiretroviral therapy in 10,000 adults in Cote dIvoire: 2-year outcomes and determinants.","volume":"22","author":"Toure","year":"2008","journal-title":"AIDS"},{"key":"R43-5-20210131","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/135965350300800505","article-title":"Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Cote dIvoire.","volume":"8","author":"Seyler","year":"2003","journal-title":"Antivir Ther"},{"key":"R44-5-20210131","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/QAD.0b013e3282f3f16d","article-title":"Lopinavir\/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.","volume":"22","author":"Delfraissy","year":"2008","journal-title":"AIDS"},{"key":"R45-5-20210131","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/01.aids.0000166091.39317.99","article-title":"Atazanavir plus ritonavir or saquinavir, and lopinavir\/ritonavir in patients experiencing multiple virological failures.","volume":"19","author":"Johnson","year":"2005","journal-title":"AIDS"},{"key":"R46-5-20210131","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1086\/587109","article-title":"Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.","volume":"46","author":"Marconi","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R48-5-20210131","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa062360","article-title":"CD4+ count-guided interruption of antiretroviral treatment.","volume":"355","author":"El-Sadr","year":"2006","journal-title":"N Engl J Med"},{"key":"R50-5-20210131","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/01.qai.0000219777.04927.50","article-title":"Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa.","volume":"42","author":"Danel","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R54-5-20210131","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(03)12655-4","article-title":"Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk.","volume":"361","author":"Murray","year":"2003","journal-title":"Lancet"},{"key":"R58-5-20210131","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/510090","article-title":"Viral load testing in resource-limited settings.","volume":"44","author":"Schooley","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R59-5-20210131","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1086\/510073","article-title":"HIV viral load monitoring in resource-limited regions: optional or necessary?","volume":"44","author":"Calmy","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R61-5-20210131","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/QAD.0b013e328137709e","article-title":"The cost effectiveness of antiretroviral treatment strategies in resource-limited settings.","volume":"21","author":"Bishai","year":"2007","journal-title":"AIDS"},{"key":"R64-5-20210131","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1001\/archinternmed.2008.1","article-title":"Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis.","volume":"168","author":"Bendavid","year":"2008","journal-title":"Arch Intern Med"},{"key":"R65-5-20210131","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S0140-6736(08)60607-8","article-title":"Monitoring antiretroviral failure in resource-poor settings.","volume":"371","author":"Moore","year":"2008","journal-title":"Lancet"},{"key":"R66-5-20210131","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/QAI.0b013e3181342564","article-title":"Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world.","volume":"46","author":"Vijayaraghavan","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R67-5-20210131","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1371\/journal.pmed.0050053","article-title":"The impact of monitoring HIV patients prior to treatment in resource-poor settings: insights from mathematical modelling.","volume":"5","author":"Hallett","year":"2008","journal-title":"PLoS Med"},{"key":"R68-5-20210131","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1086\/314503","article-title":"Variability in repeated consecutive measurements of plasma human immunodeficiency virus RNA in persons receiving stable nucleoside reverse transcriptase inhibitor therapy or no treatment.","volume":"178","author":"Bartlett","year":"1998","journal-title":"J Infect Dis"},{"key":"R69-5-20210131","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1086\/514250","article-title":"Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells\/mm3 (ACTG 175). AIDS Clinical Trials Group Protocol 175 Team.","volume":"177","author":"Lathey","year":"1998","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"R70-5-20210131","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1002\/cyto.b.20397","article-title":"African regional external quality assessment for CD4 T-cell enumeration: development, outcomes, and performance of laboratories.","volume":"74","author":"Glencross","year":"2008","journal-title":"Cytometry B Clin Cytom"},{"key":"R71-5-20210131","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/QAD.0b013e3283262a78","article-title":"Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda.","volume":"23","author":"Reynolds","year":"2009","journal-title":"AIDS"},{"key":"R72-5-20210131","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/QAI.0b013e318186eb18","article-title":"CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy.","volume":"49","author":"Moore","year":"2008","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00126334-201007010-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:19:00Z","timestamp":1786040340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00126334-201007010-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,1]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3181d0db97","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7,1]]}}}